Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension

References

• Blood Pressure Lowering Treatment Trialists’ Collaboration. Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet355, 1955–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA289(18), 2363–2369 (2003).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profile. Am. Heart J.121, 293–298 (1991).
   PubMed Web of Science ®Google Scholar
• Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. Br. Med. J.317, 167–171 (1998).
   PubMed Web of Science ®Google Scholar
• Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens.10(1), 1–8 (1997).
   PubMed Web of Science ®Google Scholar
• Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J. Hypertens. Suppl.24(1), S115–S121 (2006).
   PubMedGoogle Scholar
• Williams B. Recent hypertension trials. J. Am. Coll. Cardiol.45(6), 813–827 (2005).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C et al; for The Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch. Intern. Med.165, 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J. Hum. Hypertens.19, 331–339 (2005).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Volpe M. Treating hypertension with angiotensin II receptor blockers: a step ahead of blood pressure reduction? High Blood Press. Cardiovasc. Prev.12(1), 9–15 (2005).
   Google Scholar
• Volpe M, Musumeci MB, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J. Hypertens.21, 1429–1443 (2003).
   PubMed Web of Science ®Google Scholar
• Volpe M. Angiotensin II: an amplifier of cardiovascular risk. Curr. Hypertens. Rep.6(4), 247–248 (2004).
   PubMed Web of Science ®Google Scholar
• Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin. Ther.20, 671–681 (1998).
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Neutel JM, Davidai G, Giles TD. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J. Clin. Hypertens. (Greenwich)5, 322–329 (2003).
   PubMedGoogle Scholar
• [No Authors listed]. 2003 European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Lorenzo O, Ruperez M et al. Role of the renin–angiotensin system in vascular diseases: expanding the field. Hypertension38, 1382–1387 (2001).
   PubMed Web of Science ®Google Scholar
• Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol. Rev.45, 205–211 (1993).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Fox KM; for the European Trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease (EUROPA) Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362(9386), 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE et al. for the PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351(20), 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med.333(25), 1670–1676 (1995).
   PubMed Web of Science ®Google Scholar
• Vantrimpont P, Rouleau JL, Wun CC et al. for the SAVE Investigators. Additive beneficial effects of β-blockers to angiotensin-converting enzyme inhibitors in the Survival And Ventricular Enlargement (SAVE) Study. J. Am. Coll. Cardiol.29(2), 229–236 (1997).
   PubMed Web of Science ®Google Scholar
• [No Authors listed]. Effect of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. The of the Cooperative North Scandinavian Enalapril Survival (CONSENSUS) Trial Study Group. N. Engl. J. Med.316, 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• SOLVD Investigators. Effect of enalapril on survival in patients with Angiotensin II AT2 receptor subtype reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr. Cardiol. Rep.2(3), 258–262 (2000).
   PubMedGoogle Scholar
• Boehm M, Nabel EG. Angiotensin-converting enzyme 2 – a new cardiac regulator. N. Engl. J. Med.347(22), 1795–1797 (2002).
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L et al; for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet355, 1575–1581 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs on cardiovascular mortality and morbidity in elderly patients with hypertension: the Swedish Trial in Old Patients with Hypertension-2 (STOP-2). Lancet354, 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Niklason A, Hedner T, Niskanen L, Lanke J; for the Captopril Prevention Project (CAPPP) Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients – a subanalysis of the Captopril Prevention Project (CAPPP). J. Hypertens.22(3), 645–652 (2004).
   PubMed Web of Science ®Google Scholar
• Jong P, Yusuf S, Rousseau MF et al; for the X-SOLVD Investigators. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. The Extended-Studies Of Left Ventricular Dysfunction (X-SOLVD). Lancet361(9372), 1843–1848 (2003).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I (X-CONSENSUS). Eur. Heart J.20(2), 136–139 (1999).
   PubMed Web of Science ®Google Scholar
• Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature417, 822–828 (2002).
   PubMed Web of Science ®Google Scholar
• Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol. Rev.76, 425–536 (1996).
   PubMed Web of Science ®Google Scholar
• Allen AM, McGregor DP, Chai SY et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol.32, 339–344 (1992).
   PubMed Web of Science ®Google Scholar
• Zhuo J, McGregor DP, Mendelsohn FAO. Comparative distribution of angiotensin II receptor subtypes in mammalian adrenal glands. In: Adrenal Glands, Vascular System and Hypertension. Vinson GP, Anderson DC (Eds). Melbourne Journal of Endocrinology, Australia 53–68 (1996).
   Google Scholar
• Malmqvist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. J. Hypertens.19(6), 1167–1176 (2001).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al; for The LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial. Lancet2363(9426), 2022–2031 (2004).
   Google Scholar
• Lithell H, Hansson L, Skoog I et al; for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21(5), 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al; for the Morbidity and Mortality after Stroke, Eprosartan compared with nitrendipine for Secondary prevention (MOSES) Study Group. Principal results of a prospective randomized controlled study. Stroke36(6), 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Lehto M, Snapinn S, Dickstein K et al; for the OPTIMAAL Investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the Optimal Trial In Myocardial Infarction With The Angiotensin II Antagonist Losartan (OPTIMAAL) experience. Eur. Heart J.26(4), 350–356 (2005).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray J, Velazquez EJ et al; for the Valsartan In Acute Myocardial Infarction Trial (VALIANT) Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349, 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J et al; for the Irbesartan Microalbuminuria Type 2 Diabetes Mellitus In Hypertensive Patients (IRMA2) Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med.345, 870–878 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker L, Clarke W et al; for the Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al; for the Reduction In End-points In Patients With Non-insulin-dependent Diabetes Mellitus With The Angiotensin Ii Antagonist Losartan (RENAAL) Study Investigators. Effect of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM; for the Microalbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation106, 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA et al; on behalf of The Evaluation of Losartan In The Elderly (ELITE) Study. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet349(9054), 747–752 (1997).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin II receptor blocker Valsartan in Congestive Heart Failure (Val-HeFT). N. Engl. J. Med.345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB et al; for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the candesartan cilexitil in heart failure: assessment of reduction in morbidity and mortality (CHARM) overall programme. Lancet362, 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet362, 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergen J, Swedberg K et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet362, 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al; for the CHARM Investigators and Committees. CHARM-preserved effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet362(9386), 777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Lancet363(9426), 2049–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB et al; LIFE (Losartan Intervention For Endpoint reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy. JAMA288(12), 1491–1498 (2002).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Dahlof B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation110(11), 1456–1462 (2004).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation, The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol.45(5), 705–711 (2005).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Olsen MH, Dahlof B et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J. Hypertens.20, 405–412 (2002).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al; for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet359, 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G. Therapeutic implications of recent mega-trials in hypertension: in favour of new drugs. J. Am. Soc. Nephrol. (2007) (in press).
   Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J. Hypertens.24(1), 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension43(5), 963–969 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension40(5), 609–611 (2002).
   PubMed Web of Science ®Google Scholar
• Sowers JR. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol.286(5), H1597–H1602 (2004).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P et al; for the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med.351(19), 1952–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Li D, Shinagawa K, Pang L et al. Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachycardia-induced congestive heart failure. Circulation104, 2608–2614 (2001).
   PubMed Web of Science ®Google Scholar
• Pederson OD, Bagger H, Kober L, Torp-Pederson C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation100, 376–380 (1999).
   PubMed Web of Science ®Google Scholar
• Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation107, 2926–2931 (2003).
   PubMed Web of Science ®Google Scholar
• Madrid AH, Bueno MG, Rebollo JMG et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation106, 331–336 (2002).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol.45(5), 712–719 (2005).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol.48(3), 438–445 (2006).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al; for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs64(Suppl. 2), 43–60 (2006).
   Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P et al; for the ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am. Heart J.148(1), 52–61 (2004).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G, Pagannone E. Angiotensin II-receptor antagonist in the treatment of hypertension. Curr. Hypertens. Rep.7(4), 287–293 (2005).
   PubMed Web of Science ®Google Scholar